Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
20 Jan 2014 Vemurafenib in Hairy-Cell Leukaemia Haematologic malignancies - Anticancer agents & Biologic therapy
16 Jan 2014 Current Therapeutic Options and Development strategies in Cancer Immunotherapy Immuno-oncology
13 Jan 2014 FDA Approves Trametinib in Combination with Dabrafenib for Advanced Melanoma Melanoma - Anticancer agents & Biologic therapy
13 Jan 2014 The Impact of Personalised Medicine in Elderly Patients with Cancer Personalised medicine - Cancer in Special Situations
08 Jan 2014 Personalised Medicine in Melanoma Personalised medicine - Melanoma
06 Jan 2014 Biologicals in the Treatment of Haematological Malignancies Personalised medicine - Haematologic malignancies - Anticancer agents & Biologic therapy
03 Jan 2014 Personalised Medicine in Carcinoma of Unknown Primary Personalised medicine - Carcinoma of unknown primary site
02 Jan 2014 Hints for Personalised Medicine in Genitourinary Cancers Genitourinary cancers - Personalised medicine
31 Dec 2013 FDA Authorised First Next-Generation Sequencer Personalised medicine
30 Dec 2013 European Medicines Agency Recommends Granting a Conditional Marketing Authorisation for Cabozantinib for the Treatment of Medullary Thyroid Cancer Endocrine cancers - Anticancer agents & Biologic therapy
19 Dec 2013 Systems medicine paves the way for improved treatment for AML patients Personalised medicine - Translational research - Haematologic malignancies
18 Dec 2013 Misunderstanding of Palliative Care Palliative and supportive care
17 Dec 2013 A Study of Anastrozole in Breast Cancer Chemoprevention Breast cancer - Cancer prevention
16 Dec 2013 Obinutuzumab/Chlorambucil in the First-Line Treatment of Older CLL Patients Cancer in Special Situations - Haematologic malignancies - Anticancer agents & Biologic therapy
12 Dec 2013 Phase III Study of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukaemia Haematologic malignancies - Anticancer agents & Biologic therapy